Liquid Biopsy Market Size (2025 –2030)

The Global Liquid Biopsy Market was valued at USD 9.63 billion in 2024 and is projected to reach a market size of USD 12.1 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 4.67%. 

The market for liquid biopsies is transforming the diagnostics industry with its highly accurate, rapid, and minimally invasive means of disease detection, particularly cancer. Through the examination of biomarkers such as DNA, exosomes, and cells within body fluids like blood, liquid biopsies provide a revolutionary new alternative to tissue biopsies. This technology allows for the early detection, real-time tracking, and tailored treatment approaches, which makes it a key precision medicine tool. With increasing clinical use, advancements in molecular diagnostics, and increased demand for early cancer screening, the global liquid biopsy market is developing momentum worldwide in research and clinical applications.

Key Market Insights:

Liquid biopsies can detect cancers at early stages with up to 90% accuracy, depending on cancer type and biomarker used. Liquid biopsy tests are currently validated for over 25 types of cancers, including breast, lung, colorectal, and prostate cancers.

Over 60% of oncologists in developed countries are now using liquid biopsies to monitor treatment response and disease progression.

More than 450 clinical trials involving liquid biopsy technologies are active globally, reflecting growing research and investment interest. Liquid biopsies enable real-time disease monitoring, with some tests detecting minimal residual disease (MRD) as low as 0.01% tumour DNA in blood.

Global Liquid Biopsy Market Drivers:

One of the primary drivers of the liquid biopsy market is the increasing preference for non-invasive diagnostic methods, especially in oncology.

One of the main drivers for the liquid biopsy market is the rising interest in non-invasive diagnostic technologies, particularly in oncology. In contrast to conventional tissue biopsies, which are invasive, painful, and in some instances not even possible depending on tumour location or patient health, liquid biopsies can be conducted based on simple blood draws. This ease of use dramatically enhances patient compliance and facilitates more frequent testing, which makes real-time monitoring of disease progression or treatment response possible. Liquid biopsies also minimise the risk of complications, decrease procedural costs, and reduce diagnosis time, making them an appealing choice for healthcare professionals. With early cancer detection becoming a worldwide priority, non-invasive diagnostics such as liquid biopsy are becoming critical tools in both developed and developing healthcare systems. Their use in screening, prognosis, and the choice of therapy is an ongoing expansion, driven by robust market demand.

Another major growth driver is the rapid advancement of genomic sequencing technologies and the shift towards personalised medicine.

Another key growth driver is the swift evolution of genomic sequencing technologies and the transition to personalised medicine. Liquid biopsy allows for the detection of circulating tumour DNA (ctdna), RNA, and other biomarkers, enabling highly specific genetic profiling of tumours. This ability facilitates the development of targeted therapies specific to individual patients' tumour profiles. Technologies like next-generation sequencing (NGS), artificial intelligence-enabled bioinformatics, and high-throughput platforms have dramatically enhanced the sensitivity, accuracy, and clinical relevance of liquid biopsy tests. This enables oncologists to make better treatment choices and respond to therapies in real time. The incorporation of liquid biopsy into clinical oncology and pharma R&D pipelines is transforming cancer treatment, delivering personalised treatment at greater reach and efficacy. This continuous technological development continues to drive market growth and draw massive investments from the private and public sectors.

Global Liquid Biopsy Market Restraints and Challenges:

A significant restraint in the global liquid biopsy market is the lack of standardisation and complex regulatory approval processes.

One major restraint in the global liquid biopsy market is that there is no standardisation, and that it involves complicated regulatory approval. Although tremendous promise is held by the technology, to date, there is no overarching system for verifying the accuracy, sensitivity, and clinical significance of liquid biopsy tests across platforms and providers. Such variability can result in unreliable results, and it becomes challenging for clinicians to make critical decisions based on liquid biopsy. Furthermore, regulatory agencies like the FDA demand comprehensive clinical data to clear new diagnostic devices, further delaying time-to-market and raising development expenses for manufacturers. Small firms frequently encounter financial and technical challenges when they go through these processes. Furthermore, the lack of reimbursement procedures in several countries further delays uptake, especially in resource-constrained environments. Removal of these regulatory and standardisation hurdles is critical to release the complete potential of liquid biopsy in worldwide healthcare systems.

Global Liquid Biopsy Market Opportunities:

The liquid biopsy market worldwide is on the cusp of huge growth, fueled by several upcoming opportunities. One of the most important opportunities is the emergence of multi-cancer early detection (MCED) tests, which are designed to detect multiple types of cancer using one non-invasive blood test. Such tests could fundamentally change cancer screening by allowing for earlier detection and treatment. Furthermore, the convergence of artificial intelligence (AI) and next-generation sequencing (NGS) technologies is increasing the sensitivity and specificity of liquid biopsy assays to enable more precise detection of cancer-associated biomarkers. The industry is also gaining from rising research and development investments, which are driving innovations in genomic analysis and personalised medicine. In addition, the increasing incidence of cancer around the world and the need for more minimally invasive diagnosis options are widening the clinical use of liquid biopsies. These considerations as a whole establish a positive setting for further advancement and commercialisation of liquid biopsy technology.

LIQUID BIOPSY MARKET REPORT COVERAGE:

Global Liquid Biopsy Market Segmentation:

Liquid Biopsy Market Segmentation: By Biomarker Type

• Circulating Tumour DNA
• Circulating Tumour Cells
• Exosomes and Extracellular Vesicles
• Cell-Free DNA
• RNA biomakers
• Others

The market for liquid biopsy is diversified across different biomarker types that provide distinct diagnostic and prognostic features. Circulating Tumour DNA (ctdna) is the most commonly used biomarker, with the ability for early detection and tracking of cancer-causing genetic mutations and drug resistance. Circulating Tumour Cells (CTCS) provide significant information about tumour heterogeneity and metastasis, aiding individualised treatment schedules. Exosomes and extracellular vesicles are emerging for their capability to transport molecular information such as RNA, DNA, and proteins from cancer cells. Cell-free DNA (cfdna), though comparable to ctdna, finds wider application across non-cancer applications too. RNA biomarkers such as microRNAs are being studied further for real-time monitoring and the choice of therapy. This broad panel of biomarkers makes liquid biopsy capable of enabling a broad range of clinical uses, from early diagnosis to continuous treatment monitoring.

Liquid Biopsy Market Segmentation: By Application

• Cancer Diagnosis
• Prognosis and Monitoring
• Therapy Selection
• Recurrence Detection
• Non-Cancer Applications

Applications for liquid biopsy exist throughout the whole continuum of cancer care and stretch into non-oncology sectors as well. Diagnosis of cancer is still the major application, with detection of malignancies in an early, more curable phase. Monitoring and prognosis are key applications since liquid biopsy may follow disease spread or remission without the need for invasive measures. Therapeutic choice is greatly facilitated by liquid biopsy, as genomic information from cdna or RNA biomarkers allows oncologists to select targeted therapy based on tumour genomics. It also contributes to recurrence detection, frequently before imaging methods, by identifying minimal residual disease (MRD). Outside oncology, non-cancer uses like prenatal diagnosis, infectious disease monitoring, and transplant rejection evaluation are developing areas of interest. The liquid biopsy's adaptability across a variety of clinical scenarios underscores its potential to revolutionise personalised and precision medicine.

Liquid Biopsy Market Segmentation: Regional Analysis:

• North America
• Asia-Pacific
• Europe
• South America
• Middle East & Africa

The world liquid biopsy market is experiencing vibrant growth in all key geographies due to the momentum of cancer diagnostic research advances and increased preference for minimally invasive testing. The market is led by North America, owing to high uptake from advanced healthcare infrastructure and research activities. Europe is second, with support from government healthcare schemes and a mounting cancer incidence. The Asia-Pacific region is becoming a primary growth centre, driven by rising healthcare investments and greater awareness regarding early cancer detection. South America and the Middle East & Africa are slowly increasing their market presence as access to advanced diagnostic technologies increases.

COVID-19 Impact Analysis on the Global Liquid Biopsy Market:

The COVID-19 pandemic had a dual effect on the worldwide liquid biopsy market. The market initially struggled as a result of the delay in elective procedures and clinical trial disruptions, causing a short-term lag in adoption. Nevertheless, the pandemic also emphasised the necessity for non-invasive, quick diagnostic technologies, bringing into focus the benefits of liquid biopsies in minimising patient exposure and saving healthcare resources. This change in direction hurried research and development processes, accelerating innovation in liquid biopsy technologies. With healthcare systems evolving, demand for effective and less invasive diagnostic procedures has increased, making liquid biopsies a crucial part of contemporary oncology treatment. For these reasons, the market is expected to experience strong growth in the post-pandemic period based on the lessons of the pandemic and continued focus on patient-focused, minimally invasive diagnostic treatments.

Latest Trends/ Developments:

The market for liquid biopsies is fast evolving with growth fueled by technology improvements and increased need for non-invasive diagnostic tests. Some of the major advancements are the convergence of artificial intelligence (AI) and next-generation sequencing (NGS), allowing for increased sensitivity and specificity in early cancer detection and monitoring tests. Multi-cancer early detection (MCED) tests are picking up, allowing the detection of different types of cancer using a single blood draw. Notably, the UK's National Health Service (NHS) has started adopting liquid biopsies to identify ESR1 mutations in breast cancer patients to enable targeted therapies such as elacestrant. AI platforms are also being designed to evaluate circulating tumour DNA (ctdna), providing personalised treatment recommendations and enhancing patient outcomes.  These trends highlight the direction of the market towards precision medicine, with liquid biopsies having a central role to play in revolutionising cancer diagnosis and treatment protocols.

 Key Players:

1. Guardant Health Inc.
2. Bio-Rad Laboratories Inc.
3. QIAGEN N.V.
4. F. Hoffman-La Roche Ltd.
5. Illumina, Inc.
6. Thermo Fisher Scientific Inc.
7. Exact Sciences Corporation
8. Myriad Genetics Inc.
9. Menarini Silicon Biosystems
10. Lucence Health Inc.